Results 251 to 260 of about 186,761 (273)

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Annals of Oncology, 2021
Delvys Rodriguez-Abreu, Enriqueta Felip, Manuel Domine   +2 more
exaly  

Pembrolizumab

Reactions Weekly, 2019
  +4 more sources

Pembrolizumab

Reactions Weekly, 2016
  +4 more sources

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

Annals of Oncology, 2021
Brett G M Hughes, Ralf Gutzmer, Nicolas Meyer   +2 more
exaly  

Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review

International Immunopharmacology, 2021
Dun-Chang Mo
exaly  

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Cancer Cell, 2023
exaly  

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

European Journal of Cancer, 2020
Elliot Chartash, Lokesh Jain
exaly  

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of Oncology, 2019
Caroline Robert, Adil I Daud, Anthony Joshua   +2 more
exaly  

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Annals of Oncology, 2019
Biagio Ricciuti, John V Heymach, Matthew D Hellmann   +2 more
exaly  

Pembrolizumab

Reactions Weekly, 2017
openaire   +1 more source